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Renal cell carcinoma is the common name applied to ade-
nocarcinoma of the kidney, a tumor arising in the kidney. In
recent years, the tendency to perform ultrasonography, com-
puted tomography, or even magnetic resonance imaging has
led to increased detection of small, localized, and asympto-
matic tumors.1) The current principal treatment for renal cell
carcinoma is surgical nephrectomy. For the majority of pa-
tients who have metastatic or advanced renal cell carcinoma
that is not curable surgically, chemotherapy remains of lim-
ited value because response rates of less than 20% are
achieved.2) Therefore kidney- and site-selective delivery
methods must be developed for anticancer drugs for the clin-
ical treatment of renal cell carcinoma. To enhance the effi-
cacy of anticancer drugs and to reduce their toxicity, much
attention has been focused on renal cell carcinoma. The renal
arterial administration of poly (stylene-co-maleic acid)-con-
jugated neocarzinostatin (SMANCS)/lipiodol,3,4) microcap-
sule chemoembolization,5,6) or doxorubicin-incorporated mi-
crospheres7,8) were studied to target delivery of anticancer
drugs to the unilateral kidney. The combined uses of various
anticancer drugs by intravenous and oral administration were
reported to enhance the therapeutic effects against renal cell
carcinoma.9) When the drugs were administered by the vas-
culature route, they were distributed through the whole body
via the blood stream, leading to inadequate kidney- and site-
selective drug delivery.
In the present study, we examined the kidney- and site-se-
lective delivery of 5-fluorouracil (5-FU) utilizing absorption
on the kidney surface in rats.
MATERIALS AND METHODS
Chemicals 5-FU was purchased from Nacalai Tesque,
Inc. (Kyoto, Japan). All other chemicals were of reagent
grade.
In Vivo Experiments All experiments in the present
study were carried out in accordance with the Guidelines for
Animal Experimentation of Nagasaki University. Male Wis-
tar rats (260—310 g) were anesthetized with sodium pento-
barbital (50 mg/kg i.p.). After the right peritoneum was dis-
sected about 3 cm, a cylindrical diffusion cell (i.d. 9 mm, ef-
fective area 0.64 cm2) was attached to the right kidney sur-
face with Aron Alpha (Sankyo Co., Ltd., Tokyo, Japan), and
5-FU (50 mg/ml30.1 ml) was added to the diffusion cell di-
rectly (Chart 1). The body temperature of the rats was main-
tained at 37 °C with a heat lamp during the experiment. As
control experiments, 5-FU (50 mg/ml30.1 ml) was injected
into the jugular vein. At the predetermined times, the rats
were killed, and the liver, lung, right kidney, left kidney,
spleen, heart, and lung were removed. To evaluate the in-
trarenal distribution of 5-FU, the kidney was divided from
the reniportal structure, and they were further separated into
the site under the diffusion cell and the site not under the dif-
fusion cell (Chart 2). The tissues were weighed and homoge-
nized in a two-fold volume of phosphate-buffered saline, pH
7.4.
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The present study was undertaken to elucidate the kidney- and site-selective delivery of 5-fluorouracil (5-
FU) utilizing the absorption on the kidney surface in rats. An experimental system utilizing a cylindrical diffu-
sion cell attached to the right kidney surface was established. After intravenous administration of 5-FU, the con-
centration of 5-FU in the right and left kidneys was almost the same and was rapidly eliminated. After right kid-
ney surface application of 5-FU, however, the concentration of 5-FU in the right kidney was significantly higher
than in the left kidney and other tissues. The 5-FU concentration in four sites of the right kidney after intra-
venous administration was almost the same. In contrast, 5-FU was site selectively delivered in the kidney after
kidney surface application. The blood concentration of 5-FU was low (,1.7 mg/ml) until 120 min after kidney
surface application. The maximum blood concentration of 5-FU after kidney surface application was much lower
than after intravenous administration.
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Chart 1. Experimental Procedures
5-FU Assay Procedures in Blood and Tissues The con-
centration of 5-FU in each tissue homogenate or blood was
determined by modifying the reported methods.10,11) Briefly,
the tissue homogenates (300 m l) and blood samples (300 m l)
were added to a solution of 5-bromouracil (20 mg/ml, 150 m l)
dissolved in isotonic phosphate buffer (pH 7.4) as an internal
standard, 1 M sodium acetate buffer (pH 4.8, 100 m l), and
20% anhydrous sodium sulfate (500 m l). The mixtures were
shaken with ethyl acetate (4 ml) for 10 min and centrifuged at
9003g for 10 min. The organic layers (3 ml) were collected.
Then ethyl acetate (4 ml) was added to the residue and the
mixtures were shaken for 10 min, and thereafter centrifuged
at 9003g for 10 min. The organic layers (4 ml) were col-
lected and the mixed organic layers (7 ml) were evaporated.
The extraction residues were dissolved in 500 m l of distilled
water and were washed twice with 1.0 ml of hexane. Samples
(100 m l) were injected onto the HPLC column. The recovery
rates for extraction of 5-FU from blood and each tissue ho-
mogenate were approximately 75%. The detection limits of
5-FU in the blood and each tissue homogenate were 0.2 mg/
ml. An HPLC system (LC-6A, Shimadzu Co., Ltd., Kyoto,
Japan) with a variable-wavelength UV detector (SPD-10A,
Shimadzu) was used in reverse-phase mode. The detector
wavelength, flow rate, and column temperature were set at
266 nm, 0.7 ml/min, and 25 °C, respectively. The mobile
phase consisted of 10 mM sodium acetate buffer (pH 4.0).
The stationary phase used was a YMC-Pack ODS-A A-302
column (150 mm length34.6 mm i.d., YMC Inc., Kyoto,
Japan).
Statistical Analysis Statistical comparisons were per-
formed using analysis of variance. p,0.05 was considered to
be indicative of statistical significance.
RESULTS AND DISCUSSION
5-FU is commonly used in clinical oncology practice and
is among the drugs active against renal cell carcinoma in the
extensive list of drugs reviewed by Yagoda et al.12) Therefore
we studied the feasibility of the kidney- and site-selective de-
livery of 5-FU following the application of 5-FU on the kid-
ney surface in rats. Although oral administration of 5-FU has
been used for convenience, this administration route has the
disadvantage that the oral bioavailability of 5-FU is low and
erratic.13,14) Therefore intravenous administration of 5-FU
was selected as a control for kidney surface application.
First, we established an experimental system utilizing a
cylindrical diffusion cell attached to the right kidney surface
in rats (Chart 1). This system enables us to examine drug ab-
sorption from the kidney surface without interference by ab-
sorption from the other sites. Figure 1 shows the tissue con-
centration profiles of 5-FU for up to 180 min after intra-
venous administration or kidney surface application of 5-FU.
After intravenous administration of 5-FU, the concentration
of 5-FU in the right and left kidneys was almost the same
and the drug was rapidly eliminated (Fig. 1A). After right
kidney surface application of 5-FU, on the other hand, the
concentration of 5-FU in the right kidney was significantly
higher than in the left kidney and other tissues (Fig. 1B), and
was specifically detected in the right kidney at 60, 120, and
180 min. Figure 2 shows the intrarenal distribution of 5-FU
120 min after intravenous administration or kidney surface
application of 5-FU. To evaluate the intrarenal distribution of
5-FU, the right kidney was divided from the reniportal struc-
ture, and were further separated into the site under the diffu-
sion cell and the site not under the diffusion cell (Chart 2). 5-
FU concentrations in all sites of the right kidney after intra-
venous administration of 5-FU were almost the same (Fig.
2A). In contrast, the concentration of 5-FU in site 1 after kid-
ney surface application of 5-FU was approximately 4.2-, 2.5,
and 6.2-fold higher than those in site 2, site 3, and site 4, re-
spectively (Fig. 2B).
The side effects of 5-FU are important problems to over-
come in cancer chemotherapy. The common clinical systemic
side effects of 5-FU are myelosuppression, stomatitis, nau-
sea, emesis, and diarrhea after intravenous and/or oral ad-
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Chart 2. Division of Kidney
Fig. 1. Tissue Concentration of 5-FU after Intravenous Administration (A)
or Kidney Surface Application (B) of 5-FU to Rats at a Dose of 5 mg
5-FU was determined in the right kidney (d), left kidney (s), liver (n), spleen (e),
heart (,), and lung (3). Statistical comparisons were performed using analysis of vari-
ance (∗ p,0.05, ∗∗ p,0.01, ∗∗∗ p,0.0001, significantly different from the left kidney;
N.S., not significant). Each value represents the mean6S.E. of at least four experi-
ments.
ministration,15) and they might be caused by the high initial
blood concentration of 5-FU. Accordingly, the blood concen-
tration profiles of 5-FU after intravenous administration or
kidney surface application were evaluated as an index of the
systemic side effects of 5-FU (Fig. 3). After kidney surface
application of 5-FU, a low blood concentration (,1.7 mg/ml)
was seen until 120 min. The maximum blood concentration
of 5-FU after kidney surface application was much lower
than after intravenous administration. These results suggest
that the kidney surface application of 5-FU could diminish
the systemic side effects during treatment for renal cell carci-
noma.
The direct injection route is not suitable for targeted site-
selective drug delivery with high blood flow, because directly
injected drugs are rapidly cleared from the injected site, fol-
lowed by drainage into the systemic circulation.16) On the
other hand, 5-FU was site selectively delivered to the kidney
utilizing the absorption on the kidney surface (Fig. 1B), be-
cause 5-FU was supplied from kidney surface without injur-
ing the kidney. Such information should be useful in the de-
velopment of a novel administration route for drug delivery
to targeted sites in the kidney.
In summary, we demonstrated the kidney- and site-selec-
tive delivery of 5-FU utilizing absorption on the kidney sur-
face in rats. Direct injection of drugs can injure the organs
with the syringe needle; consequently they were limited to
inject the drug continually. In contrast, kidney surface appli-
cation dose not stress the kidney, and continuous catheter ad-
ministration may be possible to enable long-term application
of 5-FU. Furthermore, kidney- and site-selective drug deliv-
ery could be utilized with drugs for the treatment of the vari-
ous renal diseases as well as renal cell carcinoma.
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Fig. 2. Intrarenal Concentration of 5-FU 120 Min after Intravenous Ad-
ministration (A) or Kidney Surface Application (B) of 5-FU to Rats at a
Dose of 5 mg
Statistical comparisons were performed using analysis of variance (∗∗ p,0.01, sig-
nificantly different from the other sites; N.S., not significant). Each value represents the
mean6S.E. of at least four experiments.
Fig. 3. Blood Concentration of 5-FU after Intravenous Administration (s)
or Kidney Surface Application (d) of 5-FU to Rats at a Dose of 5 mg
Each value represents the mean6S.E. of at least five experiments.
